Zimmer US, Inc. is a U.S. operating subsidiary of Zimmer Biomet Holdings, Inc. (NYSE: ZBH), the orthopedic-device company headquartered in Warsaw, Indiana. The Zimmer business was founded in 1927 in Warsaw, was a Bristol-Myers Squibb subsidiary from 1972 until a 2001 spin-off (Zimmer Inc. profile; Zimmer "At a Glance," 2014), and merged with Biomet in 2015 to form Zimmer Biomet. Parent-level scale: roughly 17,000 employees and FY2024 net sales of about $7.7 billion (Zimmer Biomet Q4 2024 results; ZBH 10-K). Federal contracting records list Zimmer US, Inc. — Warsaw, IN — under NAICS 339112, surgical and medical instrument manufacturing.
Products / operations. Zimmer Biomet designs, manufactures and sells orthopedic reconstruction implants, chiefly knee and hip replacement systems, plus a "S.E.T." segment (surgical products, sports medicine, extremities and trauma) and dental/spine and related surgical offerings. MarketScreener's company summary reports about 25 production sites and sales in more than 100 countries. Zimmer US, Inc. is thus a practicing operating company, not a non-practicing entity or shell licensor.
Patent-litigation posture. The tracked data show one case, all as plaintiff and none as defendant, in the District of Delaware — consistent with an operating company asserting its own patents rather than a PAE monetizing an acquired portfolio. The single appearance arose inside a two-way dispute: Conformis, Inc. sued Zimmer Biomet entities first (D. Del., August 2019), and Zimmer US, Inc. and Biomet Manufacturing, LLC then filed their own infringement suit against Conformis on November 5, 2019 (1:19-cv-02093, D. Del., Judge Andrews).
Notable case. Zimmer US, Inc. et al. v. Conformis, Inc. involved patient-specific instrumentation for knee replacement. In May 2020 the parties settled all litigation: Zimmer Biomet paid Conformis $9.6 million and the companies cross-licensed patents covering patient-specific instruments and implants (Conformis press release/SEC filing; MassDevice; Orthopedics This Week). Venue was Delaware, not the Eastern District of Texas. The litigation posture reflects competition in patient-specific orthopedic instrumentation rather than NPE assertion activity.